Fate Therapeutics, Inc. (FATE)
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf cellular immunotherapies for cancer and immune disorders. The company leverages pluripotent stem cell technology to create proprietary immune cell products designed to improve treatment efficacy and accessibility.
Company News
Fate Therapeutics announced that clinical data from its ongoing Phase 1 trial of FT819, an off-the-shelf CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) will be presented at the EULAR 2025 Congress.
Harmony Biosciences Holdings, Inc. (HRMY) reported better-than-expected earnings and revenue for the second quarter of 2024. However, the company's stock has underperformed the market so far this year, and the earnings outlook is unfavorable, leading to a Zacks Rank #5 (Strong Sell) rating.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut the price target for Spire Global, Inc. (NYSE:SPIR) from $24 to $20. Stifel analyst Erik Rasmussen maintained a Buy rating. Spire Global shares fe...
Discover the upcoming events and earnings reports in the financial market, including notable companies like Disney, Tyson Foods, and Uber.
The company's shares bounced back after a stock sale last week.